NEOS Investment Management LLC Sells 8,053 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

NEOS Investment Management LLC lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 60.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,223 shares of the company’s stock after selling 8,053 shares during the period. NEOS Investment Management LLC’s holdings in Janux Therapeutics were worth $280,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares in the last quarter. Lester Murray Antman dba SimplyRich lifted its holdings in shares of Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock valued at $1,301,000 after purchasing an additional 16,351 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares during the last quarter. Neo Ivy Capital Management bought a new stake in Janux Therapeutics in the 3rd quarter worth about $940,000. Finally, abrdn plc purchased a new position in Janux Therapeutics in the 4th quarter worth about $3,430,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Wedbush restated an “outperform” rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. BTIG Research raised their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $92.44.

Janux Therapeutics Stock Down 7.2 %

NASDAQ JANX opened at $27.00 on Tuesday. Janux Therapeutics, Inc. has a 52 week low of $26.40 and a 52 week high of $71.71. The company has a market capitalization of $1.60 billion, a P/E ratio of -23.08 and a beta of 3.23. The stock’s 50-day moving average price is $35.33 and its 200-day moving average price is $45.87.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Activity

In related news, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,002 shares of company stock worth $1,279,953 in the last three months. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.